Combining Steroids, Peptides, and SARMs: Benefits, Risks, and Safe Practices

Why Combine — The Logic

Each compound class has distinct mechanisms and distinct gaps:

The combination logic: use each class where it is genuinely superior, not where it overlaps with another. Adding LGD-4033 to a testosterone cycle primarily adds suppression — it does not add meaningful anabolic effect beyond what testosterone already provides. Adding BPC-157 to a testosterone cycle addresses the connective tissue vulnerability that testosterone creates — that is genuine complementarity.

AAS + Peptides — The Core Stack

This is the most logical and most widely used combination. It has genuine synergy — each class addresses what the other lacks.

The Core Logic

• AAS drives the anabolic environment — protein synthesis, nitrogen retention, IGF-1 elevation, anti-catabolism
• BPC-157 + TB-500 protect connective tissue — AAS produces rapid strength gains that tendons and ligaments cannot always match; repair peptides close this gap
• GH secretagogues amplify recovery — Ipamorelin before bed amplifies the nocturnal GH pulse, which is synergistic with the elevated IGF-1 environment of an AAS cycle
• Peptides do not interfere with AAS pharmacology — no receptor competition, no hormonal interaction

Standard AAS + Peptide Stack — Bulking

Standard AAS + Peptide Stack — Cutting

AAS + SARMs — When It Makes Sense

Combining AAS with SARMs is the most controversial combination — and the most commonly misapplied. The critical issue: both classes suppress testosterone. Running LGD-4033 alongside testosterone suppresses the HPG axis further — and since testosterone is already replacing natural production, this additional suppression adds little practical downside during the cycle. However it does extend the suppression duration and can make PCT harder.

The Only Genuinely Justified AAS + SARM Combinations

Test + Ostarine — Injury or Connective Tissue Support

Ostarine has documented effects on bone mineral density and connective tissue — making it useful for users with joint issues during an AAS cycle. It adds minimal androgenic load while potentially providing joint support beyond what Deca provides.

• Testosterone Enanthate 350 mg/week + Ostarine 12.5–25 mg/day × 8 weeks
• PCT: extended — both compounds suppressive

Test + MK-677 — GH Axis Without Additional Suppression

MK-677 is not a true SARM — it does not suppress testosterone. Adding it to an AAS cycle provides sustained GH/IGF-1 elevation through oral dosing, synergising with the anabolic environment without adding any HPG suppression. This is one of the cleanest AAS additions available.

• Any AAS cycle + MK-677 25 mg/day orally — can be added at any point
• No PCT modification needed for MK-677 specifically

SARMs + Peptides — The No-AAS Approach

For users not ready for injectable AAS or seeking to avoid full HPG suppression, combining SARMs with peptides covers multiple performance goals while keeping the hormonal disruption below AAS levels.

Recomposition Stack — SARMs + Peptides

Women's Stack — SARMs + Peptides

For women, this combination avoids the androgenic risks of AAS entirely while producing meaningful body composition results:

• Ostarine 10–12.5 mg/day — lowest androgenicity SARM
• MK-677 12.5–25 mg/day — body recomposition and sleep
• BPC-157 + TB-500 — recovery and connective tissue
• Tesamorelin 1 mg/day — fat loss

Triple Stack — AAS + Peptides + SARMs

Advanced users sometimes combine all three classes simultaneously. This should only be considered after significant experience with each class individually and a thorough understanding of the compounding risks.

Advanced Lean Bulk — Triple Stack

Off-Cycle — Peptides Between AAS Cycles

One of the most underused applications of peptides is between AAS cycles — maintaining body composition and recovery support during hormonal recovery without any HPG interaction.

Off-Cycle Bridge Protocol

• Weeks 1–4 (PCT): Nolvadex 40/40/20/20 mg + Ipamorelin 200 mcg before bed + BPC-157 250 mcg daily
• Weeks 5–16 (Off-cycle bridge): MK-677 25 mg/day + CJC-1295 DAC 1 mg/week + Ipamorelin before bed + BPC-157 as needed
• Purpose: GH secretagogues maintain partial anabolic environment through GH/IGF-1 while testosterone recovers naturally. BPC-157 supports ongoing tissue repair. No HPG suppression added during recovery.

Compounding Risks — What Actually Multiplies

Not all risks compound equally. Understanding which risks multiply and which remain independent determines how dangerous a combination actually is.

Bloodwork Schedule for Combined Protocols

When combining SARMs with AAS — even when testosterone is the base — monitor liver enzymes more frequently. LGD-4033 and RAD-140 have documented hepatotoxicity that is independent of and additive to oral AAS liver impact. If both oral AAS and SARMs are used simultaneously, mid-cycle liver check at week 3–4 is mandatory.

PCT for Combined Cycles

AAS Only — Standard PCT

• Wait: 14 days after last long-ester injection
• Nolvadex 40/40/20/20 mg × 4 weeks

AAS + SARMs — Extended PCT

• Wait: 14 days after last AAS injection AND 24–48 hours after last SARM dose
• Nolvadex 40 mg + Clomid 50 mg × 2 weeks
• Nolvadex 20 mg + Clomid 25 mg × 2 weeks
• Nolvadex 20 mg × 2 weeks additional if recovery bloodwork insufficient
• Duration: 6 weeks minimum

AAS + Peptides — Standard PCT (peptides do not affect timing)

• Same as AAS-only PCT — peptides do not suppress HPG axis
• Continue BPC-157 and Ipamorelin through PCT — they support recovery without hormonal interaction
• Continue MK-677 through PCT and off-cycle — no HPG interaction

For the complete PCT guide: PCT — Post Cycle Therapy: The Complete Guide.

Frequently Asked Questions